A PSEN1 genetic test looks for mutations in the presenilin-1 gene, the gene most often responsible for inherited early-onset Alzheimer's disease. Accuracy depends heavily on age of onset and family history, and most memory clinics require genetic counseling before and after the test, so a second opinion usually means more preparation than a single blood draw. PSEN1 is described by ARUP Laboratories as the most commonly mutated gene in familial early-onset Alzheimer's disease (EOFAD), though how often it turns up a mutation varies widely by study, from roughly 20% to about 70% of familial early-onset cases. That range, and what it means for someone pursuing a second opinion on a dementia diagnosis, is the subject of this article.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a PSEN1 test actually detects
- How accurate is the result, and what does a negative result mean?
- Why genetic counseling comes before the test, not after
- How to prepare for a second-opinion visit
- What to avoid when considering PSEN1 testing
- Frequently Asked Questions
What a PSEN1 test actually detects
PSEN1 testing looks for changes in the presenilin-1 gene using DNA sequencing, usually from a blood or saliva sample. A mutation here disrupts how the body processes amyloid precursor protein, leading to the buildup of amyloid plaques associated with Alzheimer's disease at an unusually young age. The test is built for a specific situation: early-onset or strongly familial Alzheimer's disease, not routine screening.
Pathology Tests Explained states plainly that PSEN1 testing is not appropriate as a general-population screen and offers no value for someone with typical late-onset Alzheimer's disease. It is meant for people who developed symptoms well before the usual late-60s-and-older pattern, or who have multiple affected relatives across generations. A second opinion that includes PSEN1 testing should start from a clear reason the test is relevant: an early age of onset, a family tree with several affected relatives, or a known mutation already identified in a relative. Without one of those factors, the test is unlikely to add useful information.
How accurate is the result, and what does a negative result mean?
Accuracy is not a single number — it shifts with the age symptoms began. According to ARUP Laboratories, clinical sensitivity is inversely related to age of onset: the test finds a causative variant far more often in someone who became symptomatic in their 30s or early 40s than in someone whose symptoms appeared closer to age 60-65. A younger onset age makes a positive result more likely; an onset closer to 65 makes the test less informative either way.
A negative result does not close the question of an inherited cause. ARUP notes that standard panels miss certain categories of mutation entirely — changes in gene regulatory regions, deep intronic variants, and low-level mosaic or somatic variants, where only a fraction of a person's cells carry the mutation. Someone with a strong family history and a negative PSEN1 result may still have an inherited form of early-onset Alzheimer's disease that current panels cannot see. This matters directly for a second opinion: a negative PSEN1 result should prompt a conversation about what the test could and couldn't rule out, not an assumption that genetics has been eliminated as a factor.
Why genetic counseling comes before the test, not after
Every source in this area treats counseling as a required step, not an optional add-on. A review in the American Journal of Medical Genetics describes genetic counseling as essential for both symptomatic patients and healthy at-risk relatives, because inherited Alzheimer's and frontotemporal dementia vary widely in symptoms and course even among relatives who carry the identical mutation. Counseling matters most before predictive testing — testing someone who has no symptoms but wants to know their risk. Pathology Tests Explained explains that counseling helps a person decide whether to test at all, and prepares them for either outcome, including what a positive result means for the chance of passing the mutation to their children.
This is not just clinical best practice; it can also be a condition of insurance coverage. Highmark's medical policy on PSEN1 testing requires documented pre-test and post-test genetic counseling by a qualified genetics professional, generally alongside criteria such as a known familial mutation or dementia onset before age 65. A second-opinion visit that skips this step may not meet coverage requirements even if the test itself gets ordered. A UCSF provider guide for ordering dementia genetic testing lays out what that counseling conversation covers before any test is ordered: a review of family history, and an explanation of how likely a genetic cause is and what the test can and cannot show. Anyone seeking a second opinion should expect this conversation to happen before or alongside testing, not skipped in favor of jumping straight to results.
How to prepare for a second-opinion visit
A second opinion works best when the clinician has material to work with, not just a diagnosis to react to. A few things to bring: Healthline notes that a primary doctor should normally refer a patient seeking a second opinion to another physician or to a multidisciplinary memory clinic or Alzheimer's Disease Research Center. If a doctor declines to make that referral, the Alzheimer's Disease Education and Referral Center can help locate one at 800-438-4380.
- A detailed family tree noting which relatives had dementia, their age at onset, and cause of death if known
- Copies of prior test results, including any imaging, cognitive testing, or genetic panels already run
- Records of current symptoms and when they started, ideally from someone who has observed changes over time
- Any known genetic results from relatives, since a mutation already identified in the family changes what testing makes sense
- A list of questions about what a positive or negative result would change about care, prognosis, or family planning
What to avoid when considering PSEN1 testing
The Alzheimer's Foundation of America has specifically warned consumers against relying on direct-to-consumer genetic tests for dementia risk, urging anyone considering genetic testing for Alzheimer's, including PSEN1, to speak with a primary care provider and a genetic counselor first. Direct-to-consumer kits are not built to interpret a PSEN1 result in the context of a family history or clinical presentation, which is exactly the context that determines whether the result means anything.
A result obtained outside a clinical setting also typically won't come with the pre- and post-test counseling that interprets what a mutation — or the absence of one — actually implies for that specific person's age of onset and family pattern. For a second opinion to be useful, the testing path should run through a clinician or memory clinic equipped to put the result in context, not around one.
Frequently Asked Questions
Can a PSEN1 test confirm Alzheimer's disease on its own?
No. It identifies a genetic mutation linked to early-onset familial Alzheimer's disease; diagnosis still depends on clinical evaluation, and a negative result doesn't rule out an inherited cause that standard panels can miss, per ARUP Laboratories.
Does insurance cover PSEN1 testing?
Coverage policies, such as Highmark's, typically require documented pre- and post-test genetic counseling plus criteria like early onset before age 65 or a known familial mutation.
Who should consider this test?
People with early-onset symptoms or a strong family history of early-onset dementia, according to Pathology Tests Explained — not people with typical late-onset Alzheimer's or no family history.
